Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.38 |
| ▸ | POLRMT | O00411 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25915354 | 0.89 | DOT1L (0.36) | DOT1LPOLRMTRIPK1 | |
| SCHEMBL25915184 | 0.84 | DOT1L (0.34) | DOT1LPOLRMTRIPK1ALDH1A1MAPK1 | |
| SCHEMBL18666890 | 0.84 | HSPA5 (0.36) | DOT1LPOLRMTRIPK1AHCY | |
| SCHEMBL20058766 | 0.80 | DOT1L (0.37) | DOT1LPOLRMTRIPK1 | |
| SCHEMBL26229880 | 0.77 | POLRMT (0.46) | MGLLDOT1LPOLRMTRIPK1ALDH1A1 | |
| SCHEMBL13696400 | 0.77 | DOT1L (0.35) | DOT1LPOLRMTALDH1A1 | |
| SCHEMBL24791779 | 0.76 | MGLL (0.42) | MGLLDOT1LRIPK1ALDH1A1MAPK1 | |
| SCHEMBL20059049 | 0.76 | POLRMT (0.55) | POLRMT | |
| SCHEMBL23960103 | 0.76 | DOT1L (0.38) | DOT1LPOLRMTRIPK1AHCY | |
| SCHEMBL24700209 | 0.76 | POLRMT (0.48) | POLRMTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | MGLL 1174/4885DOT1L 3715/4885POLRMT 138/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | MGLL 1174/4885DOT1L 3715/4885POLRMT 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.